HomeIndustriesHealthcareFDA Approves Eli Lilly’s Zepbound Drug For Weight Loss

FDA Approves Eli Lilly’s Zepbound Drug For Weight Loss

The FDA approves Eli Lilly’s (LLY) Tirzepatide drug for weight loss. The weight loss drug, Zepbound, it to be available by the end of 2023 and a one-month supply is to cost about $1,060. Zepbound should compete against Novo Nordisk’s Weogvy and Ozempic. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.

Market On Close

08 Nov 2023

SHARE

ON AIR
8:00 pm
Next Gen Investing
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
ON AIR
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor